In brief: AstraZeneca completes divestment of Synagis to Sobi

FDA raised eyebrows at Sarepta’s golodirsen NDA
Credit: Lemau Studio

AstraZeneca has completed its divestment of the US rights of Synagis (palivizumab) to Sweden’s Sobi.

As announced in November 2018, the deal also allows Sobi to participate in 50% of the future earnings of the candidate drug MEDI8897.

Speaking at the time, Sobi President and CEO Guido Oelkers said: “The addition of Synagis will become an important catalyst for Sobi’s future development and will form a powerful platform for growth in rare diseases.”